Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026
Globe Newswire•19/10/2026•07:00 ET
0
Key Highlights
- ➤Iovance (IOVA) will present five TIL platform abstracts at ESMO Congress 2026
- ➤Lifileucel plus pembrolizumab showed deep, durable responses in frontline advanced melanoma
- ➤SARATOGA registrational trial advances lifileucel in UPS and DDLPS sarcomas
- ➤Indirect comparison suggests lifileucel may approximately double four-year survival versus standard care
- ➤TILVANCE-301 Phase 3 evaluates lifileucel plus pembrolizumab in untreated advanced melanoma
Expert Statements
Noah Berkowitz, Chief Medical Officer of Iovance
“This is our first congress presentation of TIL cell therapy in two soft tissue sarcomas with significant unmet need”
Noah Berkowitz, Chief Medical Officer of Iovance
“The efficacy and durability observed in this early cohort are what moved us quickly toward our ongoing SARATOGA registrational trial of lifileucel in UPS and DDLPS. This is the broadest look yet at how Iovance’s growing TIL platform performs across solid tumors.”
Noah Berkowitz, Chief Medical Officer of Iovance
“Our Phase 2 results in frontline, advanced melanoma show deep, durable responses with a single treatment of lifileucel added to pembrolizumab”
Noah Berkowitz, Chief Medical Officer of Iovance
“These data reinforce the scientific rationale behind TILVANCE-301, our Phase 3 trial evaluating lifileucel earlier in the treatment of advanced melanoma, highlighting the opportunity this approach may offer patients who don’t achieve lasting benefit from today’s frontline treatments.”
Iovance Advances TIL Cell Therapy into a New Chapter in Solid Tumor Treatment
Two Oral Presentations to Showcase Deep, Durable Responses with TIL Cell Therapy in Frontline Melanoma and Previously Treated Soft Tissue Sarcomas
Get started
Create a free account to read the full story.